- Polyphenolic coumpounds in chemoprevention of colon cancer targets and signaling pathways2007 | Publication without faculty affiliation
- Polyphenolic coumpounds in chemoprevention of colon cancer targets and signaling pathways2007 | Faculty of Medicine in Hradec Králové
- Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes2019 | Faculty of Medicine in Pilsen
- Renal cancer2011 | First Faculty of Medicine
- Palbociclib as one of the CDK4/6 inhibitors is of undisputed importance to women with advanced HR+/HER2- breast cancer2019 | Faculty of Medicine in Pilsen
- PARP inhibitor olaparib great benefit for a defined group of patients with BRCA positive ovarian cancer2019 | Faculty of Medicine in Pilsen
- Position of targeted therapy in ovarian cancer management2013 | Third Faculty of Medicine
- PARP inhibitors in the therapy of ovarian cancer2019 | Faculty of Medicine in Pilsen
- Biomarkers in the management of lung cancer: changing the practice of thoracic oncology2023 | Faculty of Medicine in Hradec Králové
- Treatment of lung cancer with targetable mutations - new drugs and indications2023 | First Faculty of Medicine
- Niraparib expands the availability of maintenance therapy in patients with advanced high-grade ovarian cancer2022 | Faculty of Medicine in Pilsen
- Targeted treatment and immunotherapy of advanced non-small cell lung cancer2022 | First Faculty of Medicine
- Biological therapy for breast cancer2009 | First Faculty of Medicine
- Predictive and Prognostic Significance of Tumor-infiltrating Lymphocytes in Patients with Breast Cancer Treated with Neoadjuvant Systemic Therapy2014 | Faculty of Medicine in Hradec Králové
- Apoferritin/vandetanib association is long-term stable but does not improve pharmacological properties of vandetanib2021 | Faculty of Science, Second Faculty of Medicine
- Crizotinib - a novel multikinase inhibitor of signalling pathways for treatment in selected patients with non-small cell lung cancwer2013 | Faculty of Medicine in Pilsen
- Targeted therapy in HER2-positive breast cancer2013 | Faculty of Medicine in Hradec Králové
- Targeted therapy of non-small cell lung cancer2021 | Faculty of Medicine in Pilsen
- Treatment of locally advanced NSCLC in the context of current guidelines2021 | Publication without faculty affiliation
- Clinical registry TULUNG2012 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Targeted biological therapy of stomach and esophagogastric junction cancers2012 | First Faculty of Medicine
- Complete and long-term response of HER2 positive locally highly advanced metastatic breast cancer - case report2019 | Third Faculty of Medicine
- Crizotinib as a next molecularly targeted drug in non small cell lung cancer2012 | Faculty of Medicine in Pilsen
- Strategy of treatment in metastatic non-small cell lung cancer with driver mutations2016 | Faculty of Medicine in Pilsen
- Current view on the treatment of colorectal cancer2021 | Publication without faculty affiliation
- Profile of the drug Xalkori2014 | Faculty of Medicine in Pilsen
- Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment2016 | Faculty of Medicine in Pilsen
- BODIPY-based fluorescent liposomes with sesquiterpene lactone trilobolide2017 | Faculty of Medicine in Pilsen
- Targeted treatment of breast cancer2016 | First Faculty of Medicine
- A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer2018 | Faculty of Medicine in Hradec Králové